| Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party GJ Schuurhuis, M Heuser, S Freeman, MC Béné, F Buccisano, J Cloos, ... Blood, The Journal of the American Society of Hematology 131 (12), 1275-1291, 2018 | 1075 | 2018 |
| A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia SH Petersdorf, KJ Kopecky, M Slovak, C Willman, T Nevill, J Brandwein, ... Blood, The Journal of the American Society of Hematology 121 (24), 4854-4860, 2013 | 697 | 2013 |
| Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study AH Wei, SA Strickland Jr, JZ Hou, W Fiedler, TL Lin, RB Walter, A Enjeti, ... Journal of Clinical Oncology 37 (15), 1277, 2019 | 656 | 2019 |
| Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? D Araki, BL Wood, M Othus, JP Radich, AB Halpern, Y Zhou, M Mielcarek, ... Blood, The Journal of the American Society of Hematology 126 (23), 2571-2571, 2015 | 433 | 2015 |
| Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute … RB Walter, TA Gooley, BL Wood, F Milano, M Fang, ML Sorror, EH Estey, ... Journal of clinical oncology 29 (9), 1190, 2011 | 430 | 2011 |
| SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML MS Kung Sutherland, RB Walter, SC Jeffrey, PJ Burke, C Yu, H Kostner, ... Blood, The Journal of the American Society of Hematology 122 (8), 1455-1463, 2013 | 429 | 2013 |
| Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission RB Walter, SA Buckley, JM Pagel, BL Wood, BE Storer, BM Sandmaier, ... Blood, The Journal of the American Society of Hematology 122 (10), 1813-1821, 2013 | 391 | 2013 |
| Acute myeloid leukemia stem cells and CD33-targeted immunotherapy RB Walter, FR Appelbaum, EH Estey, ID Bernstein Blood, The Journal of the American Society of Hematology 119 (26), 6198-6208, 2012 | 374 | 2012 |
| Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment RB Walter, M Othus, G Borthakur, F Ravandi, JE Cortes, SA Pierce, ... Journal of clinical oncology 29 (33), 4417, 2011 | 372 | 2011 |
| CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia ML Green, WM Leisenring, H Xie, RB Walter, M Mielcarek, BM Sandmaier, ... Blood, The Journal of the American Society of Hematology 122 (7), 1316-1324, 2013 | 343 | 2013 |
| Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia X Chen, H Xie, BL Wood, RB Walter, JM Pagel, PS Becker, VK Sandhu, ... Journal of Clinical Oncology 33 (11), 1258-1264, 2015 | 274 | 2015 |
| Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis NJ Short, S Zhou, C Fu, DA Berry, RB Walter, SD Freeman, CS Hourigan, ... JAMA oncology 6 (12), 1890-1899, 2020 | 266 | 2020 |
| Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis SA Buckley, BL Wood, M Othus, CS Hourigan, C Ustun, MA Linden, ... haematologica 102 (5), 865, 2017 | 263 | 2017 |
| Measurable residual disease testing in acute myeloid leukaemia CS Hourigan, RP Gale, NJ Gormley, GJ Ossenkoppele, RB Walter Leukemia 31 (7), 1482-1490, 2017 | 254 | 2017 |
| Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia GL Uy, I Aldoss, MC Foster, PH Sayre, MJ Wieduwilt, AS Advani, ... Blood, The Journal of the American Society of Hematology 137 (6), 751-762, 2021 | 251 | 2021 |
| Gemtuzumab ozogamicin in acute myeloid leukemia CD Godwin, RP Gale, RB Walter Leukemia 31 (9), 1855-1868, 2017 | 241 | 2017 |
| Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic … RB Walter, B Gyurkocza, BE Storer, CD Godwin, JM Pagel, SA Buckley, ... Leukemia 29 (1), 137-144, 2015 | 240 | 2015 |
| Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology … RB Walter, HM Kantarjian, X Huang, SA Pierce, Z Sun, HM Gundacker, ... Journal of Clinical Oncology 28 (10), 1766, 2010 | 239 | 2010 |
| CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab … RB Walter, TA Gooley, VHJ Van Der Velden, MR Loken, JJM Van Dongen, ... Blood 109 (10), 4168-4170, 2007 | 212 | 2007 |
| Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients RB Walter, M Othus, AK Burnett, B Löwenberg, HM Kantarjian, ... Blood, The Journal of the American Society of Hematology 121 (13), 2424-2431, 2013 | 204 | 2013 |
